Harold Strait

Harold Strait's work experience includes serving as the Head of Investor Relations at American Gene Technologies International Inc. since April 2021. At AGT, they are responsible for leading the company's autologous cell therapy program for HIV (AGT103-T), which aims to provide a functional cure for the disease. Harold is actively involved in the ongoing clinical trial and eagerly awaiting data readouts for safety and efficacy. Additionally, AGT has two other near-term programs that Harold is involved in. Prior to their current role, Harold worked as a Software Engineer at Arohatech from March 2012 to March 2022.

Harold Strait holds a Bachelor's degree from Virginia Tech, although no specific timeframe or field of study is provided.